Has Paul Gordon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,094 in general payments to Paul Gordon, MD across 187 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Gordon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Gordon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Gordon, MD

Interventional Cardiology · Providence, RINPI 1568496677

Payments from drug & device makers

What this record shows

8 manufacturers reported payments, led by Edwards Lifesciences at 43.9% of the total. 2025 is the largest year on record at $3,330, 6.9 times the $485 reported in 2019.

$13,094in general payments, 2019–2025

Across 187 payments — averaging $70.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$6K
Abbott$3K
Medtronic$2K
Ancora Heart, Inc.$2K
Boston Scientific$580
W. L. Gore & Associates, Inc.$312
plus $391 from 2 others

$125,961in research payments, 2019–2025

Across 70 payments — averaging $1799.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$56K
AstraZeneca$19K
Daiichi Sankyo Inc.$19K
Biotronik Inc.$17K
Siemens Medical Solutions USA, Inc.$14K

What the payments were for

Travel & lodging$5,28440%
Food & beverage$7,80960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	77	$5,744
Abbott	30	$2,789
Medtronic(2 entities)	57	$1,672
Ancora Heart, Inc.	5	$1,606
Boston Scientific	13	$580
W. L. Gore & Associates, Inc.	2	$312
Shockwave Medical, Inc	2	$261
Teleflex LLC	1	$130

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AccuCinch$1,606
Edwards SAPIEN 3 Transcatheter Heart Valve$1,532
EVOQUE$1,312
AMPLATZER$535
COREVALVE EVOLUT R$424
SAPIEN 3 Ultra RESILIA$340
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$339
AMPLATZER AMULET$337
GORE CARDIOFORM Septal Occluder$312
CoreValve Evolut$256
RESOLUTE ONYX$170
NAVITOR$150
APOLLOTM$149
MitraClip$139
Vascular Lithotripsy$138
MANTA$130
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$123
TRICLIP$110

How this compares

$13,094 in reported general payments places this provider in the 65th percentile of 23 interventional cardiology providers in Rhode Island.

See all interventional cardiology providers in Rhode Island →

Medicare billing

Part B allowed, 2024

$227,797

Medicare patients

365

Services billed

934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	283	$248,724
JardianceEmpagliflozin	140	$109,511
XareltoRivaroxaban	36	$34,791
EntrestoSacubitril/Valsartan	36	$29,664
Atorvastatin Calcium	290	$3,313
ClopidogrelClopidogrel Bisulfate	240	$3,266
Metoprolol Succinate	224	$3,157
Metoprolol Tartrate	266	$3,153
Lisinopril	161	$1,690
Rosuvastatin Calcium	69	$1,561
Spironolactone	211	$1,546
Losartan Potassium	133	$1,506
Diltiazem 24hr Er (Cd)Diltiazem Hcl	36	$1,491
Prasugrel Hcl	21	$1,460
Bumetanide	28	$1,346

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Providence

Peter SoukasProvidence$798K
Jinnette AbbottProvidence$156K
Marwan SaadProvidence$57K
Hafiz ImranProvidence$18K
Omar HyderProvidence$9K
Anum AsifProvidence$6K
Ahmed ElkaryoniProvidence$3K
Barry SharafProvidence$3K
Mitchel SklarProvidence$2K
Saraschandra VallabhajosyulaProvidence$2K

See the full list for Rhode Island →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →